Price T Rowe Associates Inc. MD Buys 90 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Price T Rowe Associates Inc. MD grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.0% in the first quarter, Holdings Channel reports. The fund owned 277,516 shares of the company’s stock after acquiring an additional 90 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in IDEXX Laboratories were worth $149,841,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Valley National Advisers Inc. raised its position in shares of IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after buying an additional 22 shares in the last quarter. Riverview Trust Co purchased a new position in IDEXX Laboratories during the 1st quarter valued at about $26,000. Crewe Advisors LLC purchased a new position in IDEXX Laboratories during the 1st quarter valued at about $26,000. DSM Capital Partners LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $33,000. Finally, Venturi Wealth Management LLC raised its holdings in IDEXX Laboratories by 226.3% in the fourth quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock worth $34,000 after buying an additional 43 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Down 0.1 %

Shares of NASDAQ IDXX traded down $0.32 during mid-day trading on Monday, reaching $469.39. The company had a trading volume of 208,991 shares, compared to its average volume of 475,179. The business’s 50-day moving average is $493.61 and its 200-day moving average is $516.90. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. The stock has a market cap of $38.77 billion, a price-to-earnings ratio of 45.38, a price-to-earnings-growth ratio of 3.84 and a beta of 1.32. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The company had revenue of $964.10 million for the quarter, compared to analysts’ expectations of $965.43 million. Equities analysts expect that IDEXX Laboratories, Inc. will post 11 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the sale, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.11% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on IDXX. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Morgan Stanley cut their target price on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research report on Tuesday, May 14th. Barclays cut their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Finally, BTIG Research began coverage on shares of IDEXX Laboratories in a research report on Thursday. They issued a “buy” rating and a $580.00 price target for the company. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $585.89.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.